Compass Pathways (NASDAQ:CMPS) Price Target Cut to $18.00 by Analysts at Canaccord Genuity Group

Compass Pathways (NASDAQ:CMPS) had its price target decreased by Canaccord Genuity Group from $20.00 to $18.00 in a research report released on Thursday,Benzinga reports. Canaccord Genuity Group currently has a buy rating on the stock.

A number of other research analysts have also issued reports on the company. Lifesci Capital raised Compass Pathways to a “strong-buy” rating in a report on Thursday, February 12th. Royal Bank Of Canada increased their target price on shares of Compass Pathways from $21.00 to $22.00 and gave the company an “outperform” rating in a report on Wednesday, February 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Compass Pathways in a research report on Wednesday, January 21st. HC Wainwright raised their price objective on shares of Compass Pathways from $40.00 to $70.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. Finally, Morgan Stanley cut their target price on shares of Compass Pathways from $18.00 to $16.00 and set an “overweight” rating for the company in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $21.63.

Compass Pathways Stock Up 0.4%

CMPS opened at $5.64 on Thursday. The stock has a market capitalization of $541.55 million, a P/E ratio of -1.83 and a beta of 1.90. Compass Pathways has a one year low of $2.25 and a one year high of $8.90. The business’s 50-day simple moving average is $6.70 and its 200-day simple moving average is $6.29. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.23 and a current ratio of 0.77.

Compass Pathways (NASDAQ:CMPS) last issued its quarterly earnings data on Tuesday, March 24th. The company reported ($1.00) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.59). Analysts anticipate that Compass Pathways will post -2.33 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Persistent Asset Partners Ltd purchased a new stake in shares of Compass Pathways during the 4th quarter valued at about $38,000. Advisory Services Network LLC acquired a new stake in Compass Pathways in the third quarter valued at $41,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Compass Pathways in the 4th quarter valued at about $47,000. China Universal Asset Management Co. Ltd. raised its stake in Compass Pathways by 46.7% during the second quarter. China Universal Asset Management Co. Ltd. now owns 18,272 shares of the company’s stock valued at $51,000 after buying an additional 5,817 shares in the last quarter. Finally, BIT Capital GmbH bought a new position in Compass Pathways during the 3rd quarter worth approximately $54,000. 46.19% of the stock is owned by hedge funds and other institutional investors.

More Compass Pathways News

Here are the key news stories impacting Compass Pathways this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” rating with a $70 price target and published quarterly EPS estimates for 2027 (Q1 -$0.42, Q2 -$0.27, Q3 -$0.18, Q4 -$0.08), signaling strong analyst conviction that value will increase despite near-term losses. Read More.
• Neutral Sentiment: Media coverage discusses the upcoming FDA review meeting for COMP360 (Compass’s psilocybin therapy candidate). The meeting outcome is uncertain — it could be a major catalyst if favorable, or introduce volatility if concerns are raised. Read More.
• Negative Sentiment: Canaccord cut its price target from $20 to $18 (still a “Buy”), a downgrade in expectations that may weigh on sentiment despite the maintained rating. Read More.
• Negative Sentiment: Morgan Stanley lowered its target from $18 to $16 but kept an “Overweight” rating; another target trim that may pressure short-term sentiment even though the firm remains constructive. Read More. Read More.

About Compass Pathways

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.